A Study of Darunavir in the Presence of Cobicistat When Administered as a Fixed Dose Combination Under Fed Conditions
Status:
Completed
Trial end date:
2021-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the single-dose Pharmacokinetic (PK) and
bioequivalence of darunavir (DRV) in the presence of cobicistat (COBI) when administered as a
scored fixed dose combination (FDC) tablet (DRV/COBI) compared to the co-administration as
the separate available tablet formulations (DRV and COBI), under fed conditions in healthy
participants.